Symptom Desk

North Dakota enacts $25 monthly insulin price cap

North Dakota enacts $25 monthly insulin price cap

North Dakota has joined a growing bipartisan effort to curb soaring drug costs by imposing a monthly insulin price cap of $25 for patients, marking a rare area of agreement between Democrats and Republicans amid long-standing disputes over healthcare intervention.

The Kritzberger family, who have farmed in the Red River Valley for over a century, exemplifies the financial strain families face. Their daughter, Nina, was diagnosed with Type 1 diabetes at age 7. Since then, the family has spent thousands annually on insulin, supplies, and medical care—despite having insurance. Ang Kritzberger, Nina’s mother, still remembers the first 60 days after the diagnosis, when she slept by her daughter’s bedside, monitoring her blood sugar every two hours.

“We’re in an incredible amount of debt,” Ang Kritzberger said while walking through their fields of sugar beets and soybeans. The financial burden is widespread. Federal data shows that by 2018, patients with private insurance faced average out-of-pocket costs of $470 per year for insulin. Though prices eased slightly to $220 annually by 2025, the cost remains overwhelming for many.

The new cap in North Dakota limits monthly insulin costs for patients, regardless of insurance deductibles. For families like the Kritzbergers, this provides protection against future price increases and eases the constant stress of managing a chronic illness. Nina, now 17, lists the essentials she must always carry: insulin, a backup pump, a glucose monitor, and emergency supplies. “What if my pump doesn’t work?” she said. “Then I have to bring a testing kit. What if I go low? I need Gatorade, glucose.” A missed dose of insulin could land her in the hospital. “My body would start attacking itself and start shutting down,” she said. “And then I would die.”

States and Biden push insulin price caps

Momentum for insulin price caps grew after years of public outrage over escalating costs. In 2019, Colorado became the first state to cap copays at $100 for a 30-day supply. In 2022, President Joe Biden signed legislation capping insulin at $35 per month for Medicare patients. However, efforts to extend this cap to private insurance failed in Congress due to Republican opposition.

In North Dakota, state Sen. Sean Cleary, a Republican, co-sponsored the insulin bill despite resistance from insurers and business groups. “Typically, Republicans are more on the free-market side of things, Democrats are more supportive of intervening,” Cleary said. “But in this case, I think there was broad-enough agreement that this market just wasn’t functioning for folks.”

Health insurers argued that capping insulin costs would raise premiums for everyone. Yet data from a similar cap for state employees showed minimal impact on premiums. The bill passed last year with overwhelming bipartisan support, reflecting widespread frustration with drugmakers and insurers.

State Rep. Carrie McLeod, a Republican and diabetes educator, criticized the healthcare system’s profit-driven focus. “The insurance companies started out to really help people with catastrophic needs, but things have gotten out of control,” McLeod said. Families like the Kritzbergers testified at the Capitol, traveling hours to share their experiences. Ang Kritzberger recalled feeling outnumbered at first—just her against industry lobbyists. Still, the bill’s passage proved that even in a conservative state, common ground could be found.

Bipartisan momentum grows for national drug reforms

Nationally, support for drug price regulation is rising. About 7 in 10 U.S. adults, including 68% of Republicans and 77% of Democrats, said in a KFF survey earlier this year that there isn’t enough government regulation to limit the price of prescription drugs. Congress is now considering a national insulin cap, with bipartisan backing, including from Sen. Kevin Cramer, a North Dakota Republican.

The Kritzberger farm, like many in the Red River Valley, has adapted over generations. Once focused on livestock, the family now grows sugar beets, soybeans, and grains, crops requiring careful financial management. Beyond farm expenses, the family’s annual out-of-pocket costs for diabetes care, including insulin, supplies, and medical appointments, exceed $8,000.

Limits still leave gaps for millions

The state’s insulin cap applies only to state-regulated health plans, excluding insurance provided by larger employers, which fall under federal rules. Still, 29 states have enacted similar measures. The cap limits monthly insulin costs to $25, offering protection against future price spikes and reducing the stress of managing a chronic illness.

Advocacy groups, including the American Diabetes Association, have long pushed for out-of-pocket caps and other protections as insulin prices surged. About one-fifth of the estimated 40 million Americans with diabetes rely on insulin, a drug available for over a century. Yet rising costs forced patients to pay hundreds or thousands annually, until public backlash led to modest price reductions. By 2025, average yearly out-of-pocket costs for those with private insurance had dropped to $220, though the financial burden remains severe for many.

Leave a Comment

Your email address will not be published. Required fields are marked *